AI assistant
Context Therapeutics Inc. — Director's Dealing 2023
Feb 22, 2023
34269_dirs_2023-02-21_3bc851ff-dedd-43b2-ae38-91076c379a8b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Context Therapeutics Inc. (CNTX)
CIK: 0001842952
Period of Report: 2023-02-21
Reporting Person: Lehr Martin A. (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-21 | Common Stock | P | 5823 | $0.8415 | Acquired | 159701 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 820190 | Indirect |
Footnotes
F1: The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2022.
F2: The price reported above is a weighted average price. These shares were acquired in several transactions at prices ranging from $0.8154 - $0.8470. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.